Author:
Hren M. Grace,Khattri Saakshi
Reference5 articles.
1. JAK-inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects;Klein;J Dtsch Dermatol Ges,2022
2. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials;Guttman-Yassky;Lancet,2021
3. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial;Simpson;Lancet,2020
4. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program;Simpson;Am J Clin Dermatol,2021
5. Advances in treating psoriasis in the elderly with small molecule inhibitors;Cline;Expert Opin Pharmacother,2017